Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3693 | Staff Wellbeing Centres Wiki | 0.45 |
| drug4437 | conjunctival RT PCR Wiki | 0.45 |
| drug3288 | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.08 |
| D007249 | Inflammation NIH | 0.08 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 5 clinical trials
The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries. In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment. This study is a phase I clinical trial. The investigators intent to evaluate the safety, reactogenicity and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) .
Description: Occurrence of adverse reactions post-vaccination
Measure: Safety indexes of adverse reactions Time: 0-7 days post-vaccinationDescription: Occurrence of adverse events post-vaccination
Measure: Safety indexes of adverse events Time: 0-28 days post-vaccinationDescription: Occurrence of serious adverse events post-vaccination
Measure: Safety indexes of SAE Time: 0-28 days, within 6 mouths post-vaccinationDescription: Occurrence of abnormal changes of laboratory safety examinations
Measure: Safety indexes of lab measures Time: pre-vaccination, day 7 post-vaccinationDescription: Geometric mean titer（GMT）of S-specific antibodies against 2019 novel coronavirus tested by ELISA in serum
Measure: Immunogencity indexes of GMT(ELISA) Time: day14,28，month 3,6 post-vaccinationDescription: Geometric mean titer（GMT）of S-specific antibodies against 2019 novel coronavirus tested by pseudoviral neutralization test method in serum
Measure: Immunogencity indexes of GMT(pseudoviral neutralization test method) Time: day14,28，month 6 post-vaccinationDescription: the seropositivity rates of S-specific antibodies against 2019 novel coronavirus tested by ELISA in serum
Measure: Immunogencity indexes of seropositivity rates(ELISA) Time: day14,28，month 3,6 post-vaccinationDescription: the seropositivity rates of S-specific antibodies against 2019 novel coronavirus tested by pseudoviral neutralization test method in serum
Measure: Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) Time: day14,28，month 6 post-vaccinationDescription: Geometric mean fold increase（GMI）of S-specific antibodies against 2019 novel coronavirus tested by ELISA in serum
Measure: Immunogencity indexes of GMI(ELISA) Time: day14,28，month 3,6 post-vaccinationDescription: Geometric mean fold increase（GMI）of S-specific antibodies against 2019 novel coronavirus tested by pseudoviral neutralization test method in serum
Measure: Immunogencity indexes of GMI(pseudoviral neutralization test method) Time: day14,28，month 6 post-vaccinationDescription: Geometric mean concentration（GMC）of anti-Ad5 vector neutralizing antibody responses
Measure: Immunogencity indexes of GMC(Ad5 vector) Time: day、14,28，month3,6 post-vaccinationDescription: Geometric mean fold increase（GMI）of anti-Ad5 vector neutralizing antibody responses
Measure: Immunogencity indexes of GMI(Ad5 vector) Time: day、14,28，month3,6 post-vaccinationDescription: specific cellular immune responses
Measure: Immunogencity indexes of cellular immune Time: day 14, 28,month 6 post-vaccinationDescription: Consistency analysis of S-specific antibodies against 2019 novel coronavirus tested by ELISA against those tested by pseudoviral neutralization test method
Measure: Consistency analysis(ELISA and pseudoviral neutralization test method) Time: day,14,28, month 6 post-vaccinationDescription: Relationship between Geometric mean titer (GMT) of S protein-specific antibodies against 2019 novel coronavirus and vaccine dose among study groups
Measure: Dose-response relationship（Humoral immunity） Time: day14,28，month 3,6 post-vaccinationDescription: Persistence analysis of anti-S protein antibodies among study groups
Measure: Persistence analysis of anti-S protein antibodies Time: day14,28，month 3,6 post-vaccinationDescription: Relationship between the appearance time of S-specific antibodies against 2019 novel coronavirus and the vaccination dose.
Measure: Time-dose-response relationship（Humoral immunity） Time: day14,28，month 3,6 post-vaccinationDescription: Relationship between cellular immune levels against 2019 novel coronavirus and vaccine dose among study groups
Measure: Dose-response relationship（ cellular immunity） Time: day 14, 28,month 6 post-vaccinationDescription: Persistence analysis of specific cellular immune response
Measure: Persistence analysis of cellular immuse Time: day 14, 28,month 6 post-vaccinationDescription: Relationship between the appearance time of cellular immunity against 2019 novel coronavirus and the vaccination dose.
Measure: Time-dose-response relationship（cellular immunity） Time: day 14, 28,month 6 post-vaccinationThis study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to <55 and 65 to <85 years of age，with the randomized, observer-blind, dose-escalation design
Description: The occurrence of Solicited AE in all groups within 0-6 days after each vaccination;
Measure: Incidence of the Solicited AE in all groups Time: 0-6 days after each vaccinationDescription: The occurrence of Unsolicited AE in all groups within 0-28 days after each vaccination.
Measure: Incidence of Unsolicited AE in all groups Time: 0-28 days after each vaccinationDescription: The occurrence of Serious adverse events (SAE) in all groups within 6 months after the final vaccination.
Measure: Incidence of Serious adverse events (SAE) in all groups Time: 6 months after the final vaccinationDescription: Geometric mean titer (GMT) of the IgG antibody against SARS-CoV-2 measured on Day 0, Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose group (ELISA method);
Measure: Geometric mean titer (GMT) of the IgG antibody against SARS-CoV-2 (ELISA method); Time: Day 0, Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: Seroconversion rate (%of subjects with 4-fold or greater increase in antibody level) of the IgG antibody against SARS-CoV-2 measured on Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose group (ELISA method );
Measure: Seroconversion rate of the IgG antibody against SARS-CoV-2(ELISA method ) Time: Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: Geometric Mean Increase Ratio (GMI) of the specific antibody against SARS-CoV-2 measured on Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose group (ELISA method);
Measure: Geometric Mean Increase Ratio (GMI) of the specific antibody against SARS-CoV-2(ELISA method); Time: Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: Geometric mean titer (GMT) of the neutralizing antibody against SARS-CoV-2 measured on Day 0, Day 14, Day 28 and Day 168 after vaccination in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose group (Pseudo-viral neutralization assay)
Measure: Geometric mean titer (GMT) of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay) Time: Day 0, Day 14, Day 28 and Day 168 after vaccination in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 14, Day 28 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose group(Pseudo-viral neutralization assay);
Measure: Seroconversion rate of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay) Time: Day 14, Day 28 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: Geometric mean increase ratio (GMI) of neutralizing antibody against SARS-CoV-2 measured on Day 14, Day 28 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose group (Pseudo-viral neutralization assay)
Measure: Geometric mean increase ratio (GMI) of neutralizing antibody against SARS-CoV-2 (Pseudo-viral neutralization assay) Time: Day 14, Day 28 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: Geometric Mean Titer (GMT) of the neutralizing antibody against adenovirus type 5 vector measured on Day 0, Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose group;
Measure: Geometric Mean Titer (GMT) of the neutralizing antibody against adenovirus type 5 vector Time: Day 0, Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: Geometric mean increase ratio (GMI) of the neutralizing antibody against adenovirus type 5 vector measured on Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose group
Measure: Geometric mean increase ratio (GMI) of the neutralizing antibody against adenovirus type 5 vector Time: Day 14, Day 28, Day 84 and Day 168 after vaccination in the one dose group and Day 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: The positive rate of IFN-γ stimulated by S protein overlapping peptide library detected by ELISpot
Measure: cellular immune response by ELISpot Time: on Day 0, Day 14, Day 28 and Day 168 in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose groupDescription: The positive rate of IFN-γ, TNF-α, and IL-2 expressed by CD4+ and CD8+ T lymphocytes stimulated by S protein overlapping peptide library detected by Intracellular Cytokine Staining (ICS);
Measure: cellular immune response by ICS Time: Day 0, Day 14, Day 28 and Day 168 in the one dose group and Day 0, 14, 28, 56, 70, 84, and 224 in the two dose groupThis study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above.
Description: The efficacy of Ad5-nCoV in preventing virologically confirmed (PCR positive) COVID-19 disease
Measure: Incidence of COVID-19 cases Time: day 28 to 12 months post vaccinationDescription: Evaluate the incidence of severe adverse events (SAE)
Measure: Incidence of SAE Time: Within 12 monthsDescription: Evaluate the efficacy of Ad5-nCoV in preventing severe COVID-19 disease caused by SARS-CoV-2 infection
Measure: Incidence of severe COVID-19 cases Time: Day 14 to 12 months post vaccinationDescription: Incidence of solicited adverse reactions within 7 days after vaccination, in a subset
Measure: Incidence of solicited adverse reactions Time: Day 0-7 post vaccinationDescription: Incidence of unsolicited adverse events within 28 days after vaccination in a subset
Measure: Incidence of unsolicited adverse events Time: Day 0-28 post vaccinationDescription: The seroconversion rate of S-RBD IgG antibody post vaccination
Measure: Immunogencity of S-RBD IgG antibody (ELISA method) Time: Day 28 post vaccinationDescription: The seroconversion rate of neutralizing antibody
Measure: Immunogencity of neutralizing antibody Time: Day 28 post vaccinationDescription: Number of cell-mediated immune response against SARS-CoV-2
Measure: Cell-mediated immune profile Time: Day 28 post vaccinationThis study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design
Description: Proportion of subjects with four-fold and higher increment of anti-receptor-binding domain antibodies [receptor-binding domain, RBD] of S-protein SARS-CoV-2).
Measure: Superiority of the vaccine Ad5-nCoV to placebo by the level of seroconversion Time: Day 28 after vaccinationDescription: Geometric mean titer of RBD и S-protein SARS-CoV-2 antibodies.
Measure: Immunogenicity of the vaccine Ad5-nCoV compared with placebo (titer of SARS-CoV-2 antibodies) Time: Day 14, 28 and after 6 months after vaccination.Description: Level of seroconversion (proportion of persons with four-fold and higher increment of RBD и S-protein SARS-CoV-2 antibodies).
Measure: Immunogenicity of the vaccine Ad5-nCoV compared with placebo (level of seroconversion) Time: Day 14, 28 and after 6 months after vaccination.Description: Geometric mean fold rise of RBD и S-protein SARS-CoV-2 antibodies.
Measure: Immunogenicity of the vaccine Ad5-nCoV compared with placebo (rise of SARS-CoV-2 antibodies) Time: Day 14, 28 and after 6 months after vaccination.Description: Quantity of T-cells.
Measure: Immunogenicity of the vaccine Ad5-nCoV compared with placebo (T-cell response) Time: Day 14, 28 and after 6 months after vaccination.Description: Frequency of confirmed COVID-19 (confirmed case of COVID-19: presence of clinical signs and positive result of laboratory test for RNA of virus SARS-CoV-2) (exploratory analysis).
Measure: Frequency of confirmed COVID-19 Time: Within 6 months after vaccination (except for COVID-19 cases within 14 days after vaccination)Description: Frequency of confirmed cases of COVID-19, requiring hospitalization. (confirmed case of COVID-19: presence of clinical signs and positive result of laboratory test for RNA of virus SARS-CoV-2) (exploratory analysis).
Measure: Frequency of confirmed cases of COVID-19, requiring hospitalization Time: Within 6 months after vaccination (except for COVID-19 cases within 14 days after vaccination)Description: Frequency of cases with severe course of COVID-19 (confirmed case of COVID-19: presence of clinical signs and positive result of laboratory test for RNA of virus SARS-CoV-2) (exploratory analysis).
Measure: Frequency of cases with severe course of COVID-19 Time: Within 6 months after vaccination (except for COVID-19 cases within 14 days after vaccination)Description: Frequency of death due to COVID-19 (exploratory analysis).
Measure: Frequency of death due to COVID-19. Time: Within 6 months after vaccination (except for COVID-19 cases within 14 days after vaccination)Description: Frequency and character of general and local postvaccinal reactions.
Measure: Reactogenicity of the vaccine Ad5-nCoV compared with placebo Time: Day 0 (day of vaccination), Day 2, Day 7Description: Frequency and character of adverse events and serious adverse events.
Measure: Frequency and character of adverse events and serious adverse events. Time: Day 0 - Month 6Description: Results of evaluation of vital parameters: Systolic blood pressure Diastolic blood pressure The researcher evaluates each of the vital parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (blood pressure) Time: Day -7-1 (Screening), Day 0, Day 2, Day 7, Day 14, Day 28, Month 6Description: Results of evaluation of vital parameters: • Heart rate. The researcher evaluates each of the vital parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (heart rate) Time: Day -7-1 (Screening), Day 0, Day 2, Day 7, Day 14, Day 28, Month 6Description: Results of evaluation of vital parameters: • Respiratory rate. The researcher evaluates each of the vital parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (respiratory rate) Time: Day -7-1 (Screening), Day 0, Day 2, Day 7, Day 14, Day 28, Month 6Description: Results of physical examination includes examination of organs and systems: General state Ears, nose, throat Skin and examination of the injection site The lymph nodes The cardiovascular system Respiratory system Nervous system Abdominal organs Kidneys and urinary system Musculoskeletal system. During the physical examination, the researcher evaluates each of the systems in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of physical examination Time: Day -7-1 (Screening), Day 0, Day 2, Day 7, Day 14, Day 28, Month 6Description: Results of electrocardiography: • Heart rate (HR) The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography (Heart rate) Time: Day -7-1 (Screening), Day 2Description: Results of electrocardiography: Intervals RR, PQ, QT QRS complex Corrected QT interval (QTcF). The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography Time: Day -7-1 (Screening), Day 2Description: Results of serum chemistry: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH). The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry (enzymes) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of serum chemistry: total bilirubin, creatinine, urea, fasting glucose. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of serum chemistry: total protein, C-reactive protein. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of complete blood count: hemoglobin The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hemoglobin) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of complete blood count: hematocrit. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hematocrit) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of complete blood count: erythrocytes. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocytes) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of complete blood count: platelets, leukocytes and leukocyte formula (neutrophils, lymphocytes, monocytes, eosinophils, basophils (absolute number). The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of complete blood count: erythrocyte sedimentation rate The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocyte sedimentation rate) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of coagulogram: activated partial thromboplastin time, prothrombin time. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of coagulogram: fibrinogen. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram (fibrinogen) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of clinical urinalysis: relative density. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (relative density) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of clinical urinalysis: pH. The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (pH) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of clinical urinalysis: leukocytes, erythrocytes, cylinders . The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of clinical urinalysis: protein . The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (protein) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of clinical urinalysis:glucose . The researcher evaluates each of the parameter in the normal / abnormal categories. Clinically significant abnormalities should be reported as adverse events.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (glucose) Time: Day -7-1 (Screening), Day 2, Day 28Description: Results of determination of immunoglobulin E serum concentrations.
Measure: To evaluate safety of the vaccine Ad5-nCoV by its effect on results of determination of immunoglobulin E serum concentrations. Time: Day -7-1 (Screening), Day 28This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and above and .
Description: Occurrence of adverse reactions post vaccination
Measure: Safety indexes of adverse reactions Time: within 14 days post each vaccinationDescription: Evaluate the Geometric mean titer (GMT) of IgG antibody
Measure: Immunogencity indexes of GMT Time: Day 28 post the second vaccinationDescription: Evaluate the Geometric mean titer (GMT) of neutralizing antibody
Measure: Immunogencity indexes of neutralizing antibody Time: Day 28 post the second vaccinationDescription: Occurrence of adverse reactions post-vaccination
Measure: Safety indexes of adverse events Time: Day 0-7,0-14,0-28 post each vaccinationDescription: Occurrence of abnormal changes of Hematological examination indexes(only fit for MID and sentinel group)
Measure: Safety indexes of Hematological examination measures Time: pre-vaccination, day 4 post each vaccinationDescription: Occurrence of abnormal changes of lBlood routine indexes (only fit for MID and sentinel group)
Measure: Safety indexes of Blood routine measures Time: pre-vaccination, day 4 post each vaccinationDescription: Occurrence of serious adverse events post-vaccination
Measure: Safety indexes of SAE Time: Within 6 months post the second vaccinationDescription: Evaluate the Geometric mean titer of IgG antibody
Measure: Immunogencity indexes of GMT Time: Day 28 post the first vaccination, pre the second vaccination ,Month 6 post the second vaccinationDescription: Evaluate the Geometric mean titer (GMT) of neutralizing antibody
Measure: Immunogencity indexes of neutralizing antibody Time: Day 28 post the first vaccination, pre the second vaccination ,Month 6 post the second vaccinationDescription: Number of cell-mediated immune response against SARS-CoV-2（IL-2）
Measure: Immunogencity indexes of cellular immune Time: Day 28 post the first vaccination, pre and day 28 post the second vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports